GB0217920D0 - Interleukin-4 Gene Expression inhibitors - Google Patents

Interleukin-4 Gene Expression inhibitors

Info

Publication number
GB0217920D0
GB0217920D0 GBGB0217920.8A GB0217920A GB0217920D0 GB 0217920 D0 GB0217920 D0 GB 0217920D0 GB 0217920 A GB0217920 A GB 0217920A GB 0217920 D0 GB0217920 D0 GB 0217920D0
Authority
GB
United Kingdom
Prior art keywords
interleukin
gene expression
expression inhibitors
inhibitors
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0217920.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of GB0217920D0 publication Critical patent/GB0217920D0/en
Priority to TW092109279A priority Critical patent/TWI296926B/zh
Priority to AT03721841T priority patent/ATE361910T1/de
Priority to PCT/US2003/012661 priority patent/WO2003091215A1/en
Priority to KR1020047017098A priority patent/KR100972304B1/ko
Priority to DE60313769T priority patent/DE60313769T2/de
Priority to KR10-2004-7017097A priority patent/KR20040104613A/ko
Priority to US10/421,511 priority patent/US7169925B2/en
Priority to EP06026815A priority patent/EP1834947A3/en
Priority to AU2003239150A priority patent/AU2003239150A1/en
Priority to EP03733867A priority patent/EP1501797B1/en
Priority to EP03721841A priority patent/EP1501796B1/en
Priority to DE60328675T priority patent/DE60328675D1/de
Priority to JP2003587780A priority patent/JP4497930B2/ja
Priority to US10/421,597 priority patent/US20040006123A1/en
Priority to ES03733867T priority patent/ES2330628T3/es
Priority to CA2483162A priority patent/CA2483162C/en
Priority to PCT/US2003/012189 priority patent/WO2003091214A1/en
Priority to AU2003225131A priority patent/AU2003225131A1/en
Priority to JP2003587779A priority patent/JP4746271B2/ja
Priority to CA002483091A priority patent/CA2483091A1/en
Priority to AT03733867T priority patent/ATE438621T1/de
Priority to ARP030101394A priority patent/AR039345A1/es
Priority to US11/947,922 priority patent/US20080132481A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
GBGB0217920.8A 2002-04-23 2002-08-02 Interleukin-4 Gene Expression inhibitors Ceased GB0217920D0 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
TW092109279A TWI296926B (en) 2002-04-23 2003-04-22 Interleukin-4 gene expression inhibitors
ARP030101394A AR039345A1 (es) 2002-04-23 2003-04-23 Derivados de acido amino-1h-indol-2-carboxilico 3-sustituidos y de acido amino-benzo(b)-tiofeno-2-carboxilico 3-sustituidos como inhibidores de la expresion del gen de la inteleuquina-4
EP03721841A EP1501796B1 (en) 2002-04-23 2003-04-23 3-(pyridinyl-amino)-1h-indole-2-carboxylic acid derivatives as interleukin-4 gene expression inhibitors
JP2003587780A JP4497930B2 (ja) 2002-04-23 2003-04-23 インターロイキン−４遺伝子発現抑制剤としての３−置換アミノ−１Ｈ−インドール−２−カルボン酸および３−置換アミノ−ベンゾ（ｂ）チオフェン−２−カルボン酸誘導体
KR1020047017098A KR100972304B1 (ko) 2002-04-23 2003-04-23 3-치환된 아미노-1Ｈ-인돌-2-카복실산 및 3-치환된 아미노-벤조(b)티오펜-2-카복실산
DE60313769T DE60313769T2 (de) 2002-04-23 2003-04-23 3-(pyridinyl-amino)-1h-indol-2-carbonsäure-verbindungen als inhibitoren der interleukin-4 genexpression
KR10-2004-7017097A KR20040104613A (ko) 2002-04-23 2003-04-23 인터루킨-4 유전자 발현 억제제로서의 3-치환된아미노-1η-인돌-2-카복실산 및 3-치환된아미노-벤조티오펜-2-카복실산 유도체
US10/421,511 US7169925B2 (en) 2002-04-23 2003-04-23 Indole derivatives as interleukin-4 gene expression inhibitors
EP06026815A EP1834947A3 (en) 2002-04-23 2003-04-23 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo[b]thiophene-2-carboxylic acid derivatives as interleukin-4 gene expression inhibitors
AU2003239150A AU2003239150A1 (en) 2002-04-23 2003-04-23 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo
EP03733867A EP1501797B1 (en) 2002-04-23 2003-04-23 3-(substituted amino)-1h-indole-2-carboxylic acid ester and 3-(substituted amino)-benzo[b]thiophene-2-carboxylic acid ester derivatives as interleukin-4 gene expression inhibitors
AT03721841T ATE361910T1 (de) 2002-04-23 2003-04-23 3-(pyridinyl-amino)-1h-indol-2-carbonsäure- verbindungen als inhibitoren der interleukin-4 genexpression
DE60328675T DE60328675D1 (de) 2002-04-23 2003-04-23 3-(substitutierte amino)-1h-indole-2-carbonsäureester und 3-(substitutierte amino)-benzoäbüthiophen-2-carbonsäureester verbindungen als inhibitoren der interleukin-4 genexpression
PCT/US2003/012661 WO2003091215A1 (en) 2002-04-23 2003-04-23 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo’ b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors
US10/421,597 US20040006123A1 (en) 2002-04-23 2003-04-23 Interleukin-4 gene expression inhibitors
ES03733867T ES2330628T3 (es) 2002-04-23 2003-04-23 Ester del acido 3-(amino sustituido)-1h-indol-2-carboxilico y derivados del ester del acido 3-(amino sustituido)-benzo(b)tiofeno-2-carboxilico como imhibidores de expresion del gen de interleucina-4.
CA2483162A CA2483162C (en) 2002-04-23 2003-04-23 Use of 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino benzo[b]thiophene-2-carboxylic acid derivatives as il-4 inhibitors
PCT/US2003/012189 WO2003091214A1 (en) 2002-04-23 2003-04-23 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo
AU2003225131A AU2003225131A1 (en) 2002-04-23 2003-04-23 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo' b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors
JP2003587779A JP4746271B2 (ja) 2002-04-23 2003-04-23 ３−置換アミノ−１ｈ−インドール−２−カルボン酸および３−置換アミノ−ベンゾ
CA002483091A CA2483091A1 (en) 2002-04-23 2003-04-23 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo' b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors
AT03733867T ATE438621T1 (de) 2002-04-23 2003-04-23 3-(substitutierte amino)-1h-indole-2- carbonsäureester und 3-(substitutierte amino)- benzoäbüthiophen-2-carbonsäureester verbindungen als inhibitoren der interleukin-4 genexpression
US11/947,922 US20080132481A1 (en) 2002-04-23 2007-11-30 Interleukin-4 gene expression inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37530402P 2002-04-23 2002-04-23

Publications (1)

Publication Number Publication Date
GB0217920D0 true GB0217920D0 (en) 2002-09-11

Family

ID=23480336

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0217920.8A Ceased GB0217920D0 (en) 2002-04-23 2002-08-02 Interleukin-4 Gene Expression inhibitors

Country Status (6)

Country Link
US (3) US7169925B2 (https=)
JP (1) JP4746271B2 (https=)
KR (2) KR20040104613A (https=)
AR (1) AR039345A1 (https=)
GB (1) GB0217920D0 (https=)
TW (1) TWI296926B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302035D0 (sv) * 2003-07-09 2003-07-09 Biolipox Ab New compound
WO2005023246A1 (en) * 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
US7417063B2 (en) * 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
RU2256451C1 (ru) * 2004-04-21 2005-07-20 Закрытое акционерное общество "Мастерлек" Лекарственное средство для лечения атипичной пневмонии
JP2008527030A (ja) * 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類
CN101142185A (zh) * 2005-01-19 2008-03-12 比奥里波克斯公司 用于炎症治疗的吲哚
JP5275236B2 (ja) * 2006-09-29 2013-08-28 スミスクライン ビーチャム コーポレーション 置換されたインドール化合物
WO2008098096A1 (en) * 2007-02-08 2008-08-14 Boehringer Ingelheim International Gmbh Anti-cytokine heterocyclic compounds
US8786873B2 (en) * 2009-07-20 2014-07-22 General Electric Company Application server for use with a modular imaging system
CN101628842A (zh) * 2009-08-27 2010-01-20 中国人民解放军防化指挥工程学院 烷氧羰基甲氧基作为羧基保护基
US8243882B2 (en) 2010-05-07 2012-08-14 General Electric Company System and method for indicating association between autonomous detector and imaging subsystem
KR101292836B1 (ko) * 2011-03-28 2013-08-05 한국화학연구원 벤조퓨란 또는 벤조싸이오펜 유도체 및 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 척수손상 관련 질환의 예방 또는 치료용 약학적 조성물
CN105708834A (zh) * 2011-10-18 2016-06-29 株式会社爱茉莉太平洋 包含丁香脂素的sirt1活化剂
US9962251B2 (en) 2013-10-17 2018-05-08 Boston Scientific Scimed, Inc. Devices and methods for delivering implants
AU2017220184B2 (en) * 2016-02-19 2024-04-18 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
KR101833460B1 (ko) 2016-07-05 2018-04-13 충남대학교산학협력단 대식세포(macrophage)의 극성(polarization)조절에 의하여 결핵균 생존 및 증식을 억제하기 위한 조성물.
EP3655961A4 (en) * 2017-07-17 2021-09-01 Massachusetts Institute of Technology HEALTHY AND SICK BARRIER TISSUE CELL ATLAS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US499355A (en) * 1893-06-13 Machine for making beam-stirrups
US4675332A (en) * 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
FR2628425B1 (fr) * 1988-03-08 1992-04-03 Rhone Poulenc Sante Derives d'isoindolinone, leurs procedes de preparation et les medicaments les contenant
US5189054A (en) * 1990-11-02 1993-02-23 Merrell Dow Pharmaceuticals Inc. 3-amidoindolyl derivatives and pharmaceutical compositions thereof
AU641052B2 (en) * 1990-11-02 1993-09-09 Aventisub Ii Inc. 3-amidoindolyl derivatives
US5328920A (en) * 1991-04-17 1994-07-12 Hoechst-Roussel Pharmaceuticals Incorporated Substituted (pyridinylamino)-indoles
US5177088A (en) * 1991-04-17 1993-01-05 Hoechst-Roussel Pharmaceuticals Incorporated Substituted 3-(pyridinylamino)-indoles
GB9219472D0 (en) * 1992-09-15 1992-10-28 Leo Pharm Prod Ltd Chemical compounds
US5489586A (en) * 1994-03-07 1996-02-06 Warner-Lambert Company Method for treating inflammatory disease in humans
US5969146A (en) 1995-10-11 1999-10-19 Synthelabo Oxazolidin-2-one derivatives, preparation method therefor and therapeutical use thereof
US6313151B1 (en) * 1997-06-26 2001-11-06 Eli Lilly And Company Antithrombotic agents
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
US6365370B1 (en) * 1999-09-01 2002-04-02 Ortho-Mcneil Pharmaceutical, Inc. DNA encoding a human subunit 5-HT3-C of the 5-HT3 serotonin receptor

Also Published As

Publication number Publication date
US20040006123A1 (en) 2004-01-08
TW200408389A (en) 2004-06-01
KR20040106382A (ko) 2004-12-17
US20080132481A1 (en) 2008-06-05
US7169925B2 (en) 2007-01-30
KR20040104613A (ko) 2004-12-10
US20040010029A1 (en) 2004-01-15
AR039345A1 (es) 2005-02-16
KR100972304B1 (ko) 2010-07-26
JP2005529134A (ja) 2005-09-29
JP4746271B2 (ja) 2011-08-10
TWI296926B (en) 2008-05-21

Similar Documents

Publication Publication Date Title
EG25482A (en) Inhibitors
EP1549316A4 (en) HAMMER OF TFGbeta
AU2003202263A1 (en) Roh-kinase inhibitors
GB0217920D0 (en) Interleukin-4 Gene Expression inhibitors
GB0219961D0 (en) Oxytocin inhibitors
GB2412372B (en) Pyrazine-based tubulin inhibitors
EP1532133A4 (en) NF-: B INHIBITORS
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
AU2003230392A8 (en) Beta-secretase inhibitors
EP1506778A4 (en) TGF-a EXPRESSION HEMMER
AU2003256323A8 (en) Sos1 inhibitors
AU2003269984A8 (en) Protease inhibitors
IL163935A0 (en) Plasma carboxypeptidase b inhibitors
AU2003300124A8 (en) Novel nucleoside transport inhibitors
AU2003263738A8 (en) Protease inhibitors
AU2003294705A8 (en) Ntsm gene
AU2003304496A8 (en) Protease inhibitors
AU2003215235A8 (en) Cks1 inhibitors
AU2003233642A8 (en) Protease inhibitors
GB0209138D0 (en) Gene expression
EP1514924A4 (en) NEW ACYLASE GENE
GB0208299D0 (en) Improved gene expression
GB0226149D0 (en) Inhibitors
GB0224102D0 (en) Inhibitors
GB0206031D0 (en) Inhibitors

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)